Takeda Pharmaceutical Co Ltd 2024 IR
The report outlines Takeda's progress in fiscal year 2023 across its strategic imperatives of Patient, People, and Planet. Key achievements include the approval of three new therapies, including the dengue vaccine QDENGA in over 20 countries, and a 53% reduction in Scope 1 and 2 greenhouse gas emissions from a 2016 baseline. Takeda also advanced its diversity goals, with women representing 52% of the enterprise-wide workforce and 53% of the Takeda Executive Team. Additionally, the company invested in sustainable manufacturing, such as opening its first zero-emission BioLife plasma donation center in Linz, Austria.
Company: Takeda Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2024
Type: IR
Pages: 58
Takeda Pharmaceutical Co Ltd
Annual Integrated Report
The report outlines Takeda's progress in fiscal year 2023 across its strategic imperatives of Patient, People, and Planet. Key achievements include the approval of three new therapies, including the dengue vaccine QDENGA in over 20 countries, and a 53% reduction in Scope 1 and 2 greenhouse gas emissions from a 2016 baseline. Takeda also advanced its diversity goals, with women representing 52% of the enterprise-wide workforce and 53% of the Takeda Executive Team. Additionally, the company invested in sustainable manufacturing, such as opening its first zero-emission BioLife plasma donation center in Linz, Austria.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women in Management
Net Zero Target
Employees